Loading...

Keryx Biopharmaceuticals

DB:KYX
Snowflake Description

High growth potential with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KYX
DB
$404M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
KYX Share Price and Events
7 Day Returns
-0.4%
DB:KYX
-1.9%
DE Biotechs
-1.8%
DE Market
1 Year Returns
-33.4%
DB:KYX
-8.7%
DE Biotechs
-16.8%
DE Market
KYX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Keryx Biopharmaceuticals (KYX) -0.4% 4.7% 8.6% -33.4% -36.7% -72%
DE Biotechs -1.9% -4.7% -11.9% -8.7% 36.1% -4.4%
DE Market -1.8% -3.2% -9.4% -16.8% -1.6% 7.9%
1 Year Return vs Industry and Market
  • KYX underperformed the Biotechs industry which returned -8.7% over the past year.
  • KYX underperformed the Market in Germany which returned -16.8% over the past year.
Price Volatility
KYX
Industry
5yr Volatility vs Market

Value

 Is Keryx Biopharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Keryx Biopharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Keryx Biopharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Keryx Biopharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €2.65.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Keryx Biopharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Keryx Biopharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:KYX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.76
NasdaqCM:KERX Share Price ** NasdaqCM (2018-12-12) in USD $3.36
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 26.07x
Germany Market PE Ratio Median Figure of 418 Publicly-Listed Companies 16.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Keryx Biopharmaceuticals.

DB:KYX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:KERX Share Price ÷ EPS (both in USD)

= 3.36 ÷ -0.76

-4.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Keryx Biopharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Keryx Biopharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Keryx Biopharmaceuticals's expected growth come at a high price?
Raw Data
DB:KYX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
71.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.02x
Germany Market PEG Ratio Median Figure of 279 Publicly-Listed Companies 1.33x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Keryx Biopharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Keryx Biopharmaceuticals's assets?
Raw Data
DB:KYX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $-0.45
NasdaqCM:KERX Share Price * NasdaqCM (2018-12-12) in USD $3.36
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.46x
Germany Market PB Ratio Median Figure of 567 Publicly-Listed Companies 1.76x
DB:KYX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:KERX Share Price ÷ Book Value per Share (both in USD)

= 3.36 ÷ -0.45

-7.46x

* Primary Listing of Keryx Biopharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Keryx Biopharmaceuticals has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at Keryx Biopharmaceuticals's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Keryx Biopharmaceuticals's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Keryx Biopharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Keryx Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Keryx Biopharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
71.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Keryx Biopharmaceuticals expected to grow at an attractive rate?
  • Keryx Biopharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Keryx Biopharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Keryx Biopharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:KYX Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:KYX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 71.6%
DB:KYX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 24.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 17.1%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:KYX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:KYX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 297 82 1
2021-12-31 243 45 1
2020-12-31 220 18 2
2019-12-31 183 -11 3
2018-12-31 101 -77 1
DB:KYX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 94 -98 -91
2018-06-30 81 -104 -97
2018-03-31 71 -101 -162
2017-12-31 61 -93 -163
2017-09-30 51 -94 -167
2017-06-30 43 -88 -185
2017-03-31 37 -85 -143
2016-12-31 32 -87 -161
2016-09-30 28 -91 -165
2016-06-30 26 -96 -154
2016-03-31 19 -120 -136
2015-12-31 14 -127 -123

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Keryx Biopharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Keryx Biopharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:KYX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Keryx Biopharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:KYX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 0.67 0.67 0.67 1.00
2021-12-31 0.37 0.37 0.37 1.00
2020-12-31 0.12 0.14 0.10 2.00
2019-12-31 -0.09 0.11 -0.19 3.00
2018-12-31 -0.64 -0.64 -0.64 1.00
DB:KYX Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.76
2018-06-30 -0.81
2018-03-31 -1.38
2017-12-31 -1.43
2017-09-30 -1.50
2017-06-30 -1.71
2017-03-31 -1.35
2016-12-31 -1.52
2016-09-30 -1.56
2016-06-30 -1.46
2016-03-31 -1.30
2015-12-31 -1.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Keryx Biopharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Keryx Biopharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Keryx Biopharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Keryx Biopharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Keryx Biopharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Keryx Biopharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Keryx Biopharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Keryx Biopharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Keryx Biopharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Keryx Biopharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:KYX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 94.22 -90.84 109.79 37.69
2018-06-30 81.18 -97.34 106.08 39.07
2018-03-31 70.57 -162.32 102.36 39.30
2017-12-31 60.64 -163.44 99.62 37.68
2017-09-30 51.49 -166.80 93.87 31.24
2017-06-30 42.83 -184.99 91.65 30.64
2017-03-31 36.98 -143.15 86.85 28.65
2016-12-31 31.98 -161.10 84.55 29.50
2016-09-30 28.23 -165.10 83.08 31.31
2016-06-30 26.10 -154.14 82.77 33.79
2016-03-31 19.33 -136.37 83.34 34.72
2015-12-31 13.68 -123.15 81.41 36.69
2015-09-30 8.47 -125.65 93.90 34.52
2015-06-30 4.51 -130.19 90.14 44.42
2015-03-31 2.00 -125.73 81.65 46.73
2014-12-31 10.83 -111.52 70.06 51.50
2014-09-30 10.26 -88.90 43.29 55.14
2014-06-30 10.00 -69.26 31.90 44.76
2014-03-31 10.00 -58.21 23.91 41.66
2013-12-31 7.00 -46.73 19.35 34.73
2013-09-30 7.00 -35.69 13.84 29.18
2013-06-30 7.00 -25.52 10.38 22.44
2013-03-31 7.00 -18.30 8.00 19.06
2012-12-31 -25.36 7.05 20.03
2012-09-30 0.00 -27.35 7.11 21.99
2012-06-30 0.00 -32.13 7.10 26.83
2012-03-31 5.00 -31.08 6.92 29.54
2011-12-31 5.00 -28.37 6.74 27.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Keryx Biopharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Keryx Biopharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Keryx Biopharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Keryx Biopharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Keryx Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Keryx Biopharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Keryx Biopharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Keryx Biopharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Keryx Biopharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Keryx Biopharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Keryx Biopharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Keryx Biopharmaceuticals Company Filings, last reported 2 months ago.

DB:KYX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 -54.22 147.30 41.15
2018-06-30 -41.19 130.09 49.46
2018-03-31 -31.61 125.00 60.09
2017-12-31 -14.10 125.00 93.53
2017-09-30 8.96 125.00 114.00
2017-06-30 25.65 125.00 140.53
2017-03-31 -22.53 125.00 90.91
2016-12-31 -8.30 125.00 111.81
2016-09-30 21.99 125.00 132.17
2016-06-30 59.85 125.00 155.80
2016-03-31 49.40 106.52 170.53
2015-12-31 86.93 90.77 200.29
2015-09-30 121.07 0.00 102.21
2015-06-30 147.14 0.00 131.29
2015-03-31 168.54 0.00 168.84
2014-12-31 73.48 0.00 85.79
2014-09-30 98.71 0.00 118.23
2014-06-30 124.31 0.00 136.99
2014-03-31 143.92 0.00 154.92
2013-12-31 45.40 0.00 55.70
2013-09-30 58.57 0.00 67.74
2013-06-30 73.27 0.00 80.17
2013-03-31 83.87 0.00 87.34
2012-12-31 10.49 0.00 14.68
2012-09-30 16.58 0.00 20.25
2012-06-30 21.51 0.00 27.11
2012-03-31 22.58 0.00 30.91
2011-12-31 31.05 0.00 39.46
  • Keryx Biopharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Keryx Biopharmaceuticals's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Keryx Biopharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Keryx Biopharmaceuticals has less than a year of cash runway if free cash flow continues to reduce at historical rates of -14.2% each year.
X
Financial health checks
We assess Keryx Biopharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Keryx Biopharmaceuticals has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Keryx Biopharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Keryx Biopharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Keryx Biopharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Keryx Biopharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Keryx Biopharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:KYX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:KYX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Keryx Biopharmaceuticals has not reported any payouts.
  • Unable to verify if Keryx Biopharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Keryx Biopharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Keryx Biopharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Keryx Biopharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Keryx Biopharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Keryx Biopharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Keryx Biopharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Keryx Biopharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jodie Morrison
COMPENSATION $266,318
AGE 43
TENURE AS CEO 0.7 years
CEO Bio

Ms. Jodie Pope Morrison served as Chief Executive Officer and President of eGenesis, Inc. from September 2017 to November 2017. Ms. Morrison has over 20 years of strategic and operational experience in the pharmaceutical and biotech industries. Ms. Morrison served as the Chief Executive Officer and President of Tokai Pharmaceuticals, Inc., now Novus Therapeutics, Inc., or Novus from March 28, 2013 to May 2017. From December 2006 until March 2013, Ms. Morrison held other senior positions with Novus, including Chief Operating Officer, Head of Clinical Affairs and Program Operations and Vice President of Clinical Affairs and Program Operations. Since May 2017, Ms. Morrison has provided independent consulting services to venture capital, biotechnology and pharmaceutical companies. Prior to joining Novus, Ms. Morrison served as Director of Clinical Operations and Medical Affairs at Dyax Corporation or Dyax. While at Dyax, she built the clinical development team and oversaw clinical and medical operations on the hereditary angioedema and cardiothoracic surgery programs. Prior to joining Dyax, Ms. Morrison held clinical management positions at both Curis, Inc. and Diacrin, Inc. Her clinical operations experience includes programs in women's health, oncology, urology, cardiothoracic surgery, cardiac anesthesiology, allergy, immunology, neurosurgery and transplant surgery. Prior to focusing her career in clinical operations, she worked in the Cell Transplantation Laboratory at Diacrin, Inc. She has been a Director of Aileron Therapeutics, Inc. since June 2017. Ms. Morrison has been a Director of Keryx Biopharmaceuticals, Inc. since June 21, 2016 and serves as Interim Chief Executive Officer since April 27, 2018. She was Director of Novus Therapeutics, Inc. since March 2013. She previously served as a Director of Tokai Pharmaceuticals, Inc. since March 28, 2013. Ms. Morrison received a B.A. in neuroscience from Mount Holyoke College, her clinical research certification from the Boston University School of Medicine and her business training through the Greater Boston Executive Program at the MIT Sloan School of Management.

CEO Compensation
  • Jodie's compensation has increased whilst company is loss making.
  • Jodie's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Keryx Biopharmaceuticals management team in years:

2.4
Average Tenure
50.5
Average Age
  • The tenure for the Keryx Biopharmaceuticals management team is about average.
Management Team

Jodie Morrison

TITLE
Interim CEO & Director
COMPENSATION
$266K
AGE
43
TENURE
0.7 yrs

Scott Holmes

TITLE
CFO, Senior VP & Treasurer
COMPENSATION
$1M
AGE
44
TENURE
3.4 yrs

Christine Carberry

TITLE
Senior VP & COO
COMPENSATION
$2M
AGE
57
TENURE
1.9 yrs

John Neylan

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$1M
AGE
65
TENURE
3.7 yrs

Tony Chambers

TITLE
Vice President of Sales

Doug Jermasek

TITLE
Vice President of Marketing & Strategy
TENURE
2.4 yrs

Lisa Fiering

TITLE
Vice President of Human Resources
TENURE
2.8 yrs

Amy Sullivan

TITLE
Senior Vice President of Corporate Affairs
TENURE
1.8 yrs

Melissa Bradford-Klug

TITLE
Senior VP & Chief Business Officer
TENURE
1.8 yrs

Dan Olmstead

TITLE
Vice President of Payer Access
TENURE
4.9 yrs
Board of Directors Tenure

Average tenure and age of the Keryx Biopharmaceuticals board of directors in years:

2.5
Average Tenure
54
Average Age
  • The average tenure for the Keryx Biopharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Michael Rogers

TITLE
Chairman
COMPENSATION
$298K
AGE
58
TENURE
1.3 yrs

Jodie Morrison

TITLE
Interim CEO & Director
COMPENSATION
$266K
AGE
43
TENURE
2.5 yrs

Kevin Cameron

TITLE
Independent Director
COMPENSATION
$286K
AGE
50
TENURE
11.7 yrs

Dan Regan

TITLE
Independent Director
COMPENSATION
$279K
AGE
53
TENURE
5.2 yrs

Steve Gilman

TITLE
Independent Director
COMPENSATION
$279K
AGE
65
TENURE
2.8 yrs

Mike Heffernan

TITLE
Director
COMPENSATION
$266K
AGE
54
TENURE
2.5 yrs

Mark Enyedy

TITLE
Independent Director
COMPENSATION
$288K
AGE
54
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • Keryx Biopharmaceuticals insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
16. Nov 18 Sell John Neylan Individual 15. Nov 18 15. Nov 18 -1,156 €2.45 €-2,830
16. Nov 18 Sell Scott Holmes Individual 15. Nov 18 15. Nov 18 -1,155 €2.45 €-2,828
30. Oct 18 Sell John Neylan Individual 29. Oct 18 29. Oct 18 -1,253 €2.70 €-3,379
30. Oct 18 Sell Scott Holmes Individual 29. Oct 18 29. Oct 18 -1,254 €2.70 €-3,382
22. Oct 18 Sell Christine Carberry Individual 18. Oct 18 18. Oct 18 -2,040 €2.86 €-5,835
16. Aug 18 Sell Scott Holmes Individual 15. Aug 18 15. Aug 18 -1,185 €2.69 €-3,182
16. Aug 18 Sell John Neylan Individual 15. Aug 18 15. Aug 18 -1,186 €2.69 €-3,185
31. Jul 18 Sell John Neylan Individual 30. Jul 18 30. Jul 18 -1,282 €3.30 €-4,225
31. Jul 18 Sell Scott Holmes Individual 30. Jul 18 30. Jul 18 -2,354 €3.30 €-7,757
19. Jul 18 Sell Christine Carberry Individual 18. Jul 18 18. Jul 18 -2,021 €3.86 €-7,794
16. May 18 Sell Scott Holmes Individual 15. May 18 15. May 18 -1,158 €4.80 €-5,553
16. May 18 Sell John Neylan Individual 15. May 18 15. May 18 -1,158 €4.80 €-5,553
01. May 18 Sell Scott Holmes Individual 30. Apr 18 30. Apr 18 -2,407 €3.87 €-9,310
01. May 18 Sell John Neylan Individual 30. Apr 18 30. Apr 18 -1,311 €3.87 €-5,071
24. Apr 18 Sell John Neylan Individual 23. Apr 18 23. Apr 18 -1,111 €3.76 €-4,174
20. Apr 18 Sell Christine Carberry Individual 18. Apr 18 18. Apr 18 -2,026 €3.90 €-7,904
16. Feb 18 Sell Scott Holmes Individual 15. Feb 18 15. Feb 18 -5,651 €3.85 €-21,767
16. Feb 18 Sell Gregory Madison Individual 15. Feb 18 15. Feb 18 -15,318 €3.85 €-59,003
16. Feb 18 Sell John Neylan Individual 15. Feb 18 15. Feb 18 -5,652 €3.85 €-21,771
16. Feb 18 Sell Brian Adams Individual 15. Feb 18 15. Feb 18 -5,652 €3.85 €-21,771
31. Jan 18 Sell Scott Holmes Individual 29. Jan 18 29. Jan 18 -2,830 €3.90 €-11,026
31. Jan 18 Sell John Neylan Individual 29. Jan 18 29. Jan 18 -1,541 €3.90 €-6,004
31. Jan 18 Sell Brian Adams Individual 29. Jan 18 29. Jan 18 -1,541 €3.90 €-6,004
24. Jan 18 Sell John Neylan Individual 23. Jan 18 23. Jan 18 -1,322 €4.01 €-5,296
22. Jan 18 Sell Christine Carberry Individual 18. Jan 18 18. Jan 18 -9,048 €3.98 €-35,978
08. Jan 18 Sell Brian Adams Individual 05. Jan 18 05. Jan 18 -753 €3.90 €-2,935
08. Jan 18 Sell Gregory Madison Individual 05. Jan 18 05. Jan 18 -1,067 €3.90 €-4,159
X
Management checks
We assess Keryx Biopharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Keryx Biopharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Details
Name: Keryx Biopharmaceuticals, Inc.
KYX
Exchange: DB
Founded: 1997
$356,210,662
120,375,926
Website: http://www.keryx.com
Address: Keryx Biopharmaceuticals, Inc.
One Marina Park Drive,
12th Floor,
Boston,
Massachusetts, 02210,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM KERX Common Stock Nasdaq Capital Market US USD 28. Jul 2000
DB KYX Common Stock Deutsche Boerse AG DE EUR 28. Jul 2000
Number of employees
Current staff
Staff numbers
189
Keryx Biopharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/12/13 21:55
End of day share price update: 2018/12/12 00:00
Last estimates confirmation: 2018/12/12
Last earnings filing: 2018/11/08
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.